SUBSCRIPTION AGREEMENTSubscription Agreement • August 8th, 2018 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (“Agreement”), dated as of August 3, 2018, sets forth the terms and conditions upon which Quotient Limited, a company organized under the laws of Jersey (the “Company”), will issue, and Franz Walt (the “Subscriber”) will subscribe for, an aggregate of 45,000 ordinary shares (the “Shares”), of no par value per share, of the Company (for cash at a price of $7.54 per Share (the “Subscription Price”). This Agreement is being entered into prior to the close of trading on The Nasdaq Global Market on the date of this Agreement and, accordingly, the Subscription Price per Share is equal to the closing bid price of the Company’s ordinary shares as reported on the Nasdaq Global Market on August 2, 2018.
